MICHAEL EVANS: Open Payments
NPI 1790188910 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 65 payments from 17 companies in 2025. Trend: 2023 $694 · 2024 $1,012 · 2025 $1,059
Food & beverage: $1,059
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $351 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $104 |
| Axsome Therapeutics, Inc. | 6 | $103 |
| PFIZER INC. | 4 | $83 |
| Lilly USA, LLC | 5 | $80 |
| HARMONY BIOSCIENCES LLC | 3 | $49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $35 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
Products named: VRAYLAR, CAPLYTA, QULIPTA, NURTEC ODT, UBRELVY, MOUNJARO, Auvelity, WAKIX.
Industry payments across UT — which companies pay providers there.
